# Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6

> **NCT03618758** · PHASE1,PHASE2 · COMPLETED · sponsor: **Seoul National University Bundang Hospital** · enrollment: 35 (actual)

## Conditions studied

- Gastric Cancer Stage IV
- Peritoneal Carcinomatosis
- Intraperitoneal Paclitaxel
- mFOLFOX6

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** mFOLFOX6 regimen

## Key facts

- **NCT ID:** NCT03618758
- **Lead sponsor:** Seoul National University Bundang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-24
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-12-02
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-12-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03618758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03618758, "Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03618758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*